This page is updated frequently with new Cholesterol-related patent applications.
| Low molecular weight cationic lipids for oligonucleotide delivery|
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.
| Uses of oxygenated cholesterol sulfates (ocs)|
Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (mods), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (ocs), e.g.
| Anti-cholesterolemic compounds and methods of use|
The present invention provides novel compounds with hypocholesteremic activity from crude embilica officinialis (eo) extracts and methods of use. The invention also provides nutraceuticals..
| Nasal vaccine for streptococcus pneumoniae|
The present invention provides a nasal vaccine for streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of pspa, i.e.
| Nutritional composition|
A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.. .
|Infusion of insulin into a patient and diabetes mellitus medical methods based on the patients monitored analyte concentration|
Medical data provided by a physiological parameter sensor is used for management of the patient's medical condition. Analytes that may be monitored and managed include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., ck-mb), creatine, glucose, glutamine, growth hormones, hormones, ketones, lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, thyroid stimulating hormone, and troponin..
Abbott Diabetes Care Inc.
|Method and system for extracting and using moomiyo compositions|
A method and system for extraction of moomiyo from a multi-component, naturally-occurring mineral substance generally found in asian mountain ranges at elevations approximately between 1000 and 5000 meters. Bio-active compounds are extracted from said mineral substance for the medicinal applications including at least one of joint pain relief, skin care, anti-inflammation, bruise removal, decrease high blood cholesterol and high triglycerides levels, promotion of mental and physical energy, regulation of blood sugar levels, stimulation of the immune system, speeding of the recovery from sickness and wound healing therapies..
|Diether based biodegradable cationic lipids for sirna delivery|
Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.
|Pegylated 7-dehydrocholesterol derivatives|
The present invention relates to pegylated 7-dehydrocholesterol derivatives, and a composition for wrinkle alleviation and anti-aging comprising the same. The pegylated 7-dehydrocholesterol derivatives according to the present invention have improved stability and solubility in water, and thus can be effectively used as a good source for supplying vitamin d in a cosmetic composition, a pharmaceutical composition and a functional food for wrinkle alleviation and anti-aging..
Humedix Co., Ltd.
A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, hyper-ldl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group, and r1 is a hydrogen atom or a hydroxy group.. .
Daiichi Sankyo Company, Limited
Methods of using interleukin-10 for treating diseases and disorders
Methods for determining dosing parameters associated with subcutaneous administration of il-10 useful for the treatment and/or prevention of a cholesterol-related disease, disorder or condition, and pharmaceutical compositions associated therewith, are provided herein. Certain embodiments are directed to means for establishing a therapeutic range of an il-10 agent in a subject.
Armo Biosciences, Inc.
Proliposomal testosterone formulations
Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc
Compositions based on methyl cyclodextrins for the treatment and/or prevention of diseases by increasing the hdl cholesterol level
The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (ms) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the hdl cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system.
Compounds, compositions and methods useful for cholesterol mobilization
The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein..
Cerenis Therapeutics Holding Sa
Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting acyl-coa: cholesterol acyltransferase 1 (acati) activity or expression in myeloid cells.. .
Trustees Of Dartmouth College
Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University
3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
3,3′-disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.
Beta-lactam cholesterol absorption inhibitors
The present invention relates to the novel compounds represented by formula (ia) or (ib) and to their pharmaceutical preparations for the treatment of atherosclerosis and cholesterol level reduction.. .
Rudjer Boskovic Institute
Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.
Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases
The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of formulation i, and its method on in vitro and in vivo systems.
Compositions and therapeutic methods for accelerated plaque regression
The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of formula i or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin..
Use of quaternary pyridinium salts as vasoprotective agents
Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .
Endoxifen compositions and methods
The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, z- and e-guggulsterones, phospholipids, fatty acids, vitamin d, and vitamin e.
Jina Pharmaceuticals, Inc.
Ketohexokinase (khk) irna compositions and methods of use thereof
The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.
Liposome comprising at least one cholesterol derivative
More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.. .
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Process for producing 7-dehydrocholesterol and vitamin d3
According to the present invention, there can be provided a process for producing 7-dehydrocholesterol (hereinafter, “7dhc”), comprising culturing, in a medium, a 7dhc-producing labyrinthulea microorganism in which the 7dhc reducing activity is reduced or lost as compared to a parent strain through deletion, substitution, or addition of at least one base in a gene which is present in the chromosomal dna of the parent strain and encodes a protein having 7dhc reducing activity, and the microorganism produces 7dhc, allowing 7dhc to be produced and accumulated in the culture, and collecting the 7dhc from the culture; and a process for producing vitamin d3, comprising irradiating, with ultraviolet light, the 7dhc produced by the production process.. .
Kyowa Hakko Bio Co. Ltd.
Shunting of dietary lipids including cholesterol
Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body.
Boston Scientific Scimed, Inc.
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania
Cholesterol efflux capacity assessment
A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) value. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics
Cholesterol efflux capacity assessment
A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) level. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics Corporation
Measurement of serum lipoproteins
Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
Process for refining chemicals from pulp and paper mill effluent
A process for isolating at least one target compound, such as manool, geranyl linalool, ethyl guaiacol, eugenol, veratraldehyde, squalene, terpin, cholesterol, beta-sitosterol, campesterol, stigmasterol, stigmastenol and dehydroabietic acid, from biomass, the process including steps of: obtaining a condensate from a recovery evaporator, a reverse osmosis retentate of a condensate of a pulp and paper mill, or both, the condensate, retentate or both being substantially free of higher molecular weight (approximately >1000 da) cellulose and/or lignin and/or lignin-derived material; optionally ph adjusting and filtering the condensate to collect insoluble material; extracting the condensate, the collected insoluble material, or both, with solid phase extraction (spe), liquid-liquid extraction or solid-liquid extraction to produce an extract containing the at least one target compound; and optionally purifying the extract containing the at least one target compound by thermal fractionation, chromatographic separation, recrystallization ion exchange, chelation, adsorption/desorption, lyophilization and sublimation or combinations thereof. The method is particularly useful for isolating the target compounds from wastewaters produced in a kraft pulp and paper mill, especially from recovery evaporator condensates produced during the treatment of black liquor..
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Environment
Mrna therapy for pompe disease
The present invention provides, among other things, methods of treating pompe disease, including administering to a subject in need of treatment a composition comprising an mrna encoding acid alpha-glucosidase (gaa) at an effective dose and an administration interval such that at least one symptom or feature of pompe disease is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids..
Shire Human Genetic Therapies, Inc.
Methods and creating particle derivatives of hdl with reduced lipid content
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of hdl without substantially affecting ldl. These derivatives of hdl are particles with reduced lipid content, particularly reduced cholesterol content.
Method for pre-screening and correlation of underlying scarb1 gene variation to atherosclerosis in women and therapeutic use of progestational and other medications in treatment
A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the scarb1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.. .
Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated igf-1, elevated triglyceride levels, and/or elevated crp levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided.
University Of Southern California
Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein x is (ch2) or o, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis:. .
Merck Sharp & Dohme Corp.
Methods of sustaining dietary ketosis and its effects on lipid profile
The ketogenic diet (kd) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mm) without need for dietary restriction.
University Of South Florida
Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient
A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.
Liposomal formulations for allosteric akt inhibitors
Disclosed herein is a lipid nanoparticle (lnp) composition comprising (a) an akt inhibitor; (b) dspc; (c) cholesterol; and (d) peg-dmg. Also disclosed herein is a method for preparing the lipid composition using a scalable tangential flow micro-mixing technology..
Merck Sharp & Dohme Corp.
Nanosomal preparation of the complex formed by quercetin (or another flavonol, flavone or a derivative thereof) and 2-hydroxypropyl-beta-cyclodextrin for intravenous use in cerebral pathological conditions
The invention involves the preparation of cholesterol lecithin nanosomes, without propylene glycol, from the complex formed by quercetin (or another flavonol or flavone or a derivative thereof) and 2-hydroxypropyl-β-cyclodextrin, by means of a process that allows the safe, effective intravenous use thereof in the treatment of cerebral pathological conditions in adults and newborns. The preparation is safe, stabilizes the altered haemodynamic parameters in severe neonatal hypoxia in newborn pigs and is effective in protecting cerebral function in experimental parkinson's disease models and in newborn pigs subject to hypoxia..
Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
The described invention provides methods for targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.. .
Board Of Regents Of The University Of Texas System
Follow us on Twitter
This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.